Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment). RESULTS: A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P=0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group. CONCLUSIONS: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [459]
In the citing paper
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [79]
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [46]
In the citing paper
“anti-Aβ mAbs that predominantly bind to monomeric Aβ do not mediate substantial removal of plaque and lack clinical efficacy”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [42]
In the citing paper
“A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Honig et al., 2018
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 301–400 of 999
Herman, F. J., Westfall, S., Brathwaite, J. S., & Pasinetti, G. M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00867 · Cited by 44
Xing, Z., Zuo, Z., Hu, D., Zheng, X., Wang, X., Yuan, L., Zhou, L., Qi, F., & Yao, Z. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.09.015 · Cited by 39
Vascular risk burden is a key player in the early progression of Alzheimer’s disease
Ferrari‐Souza, J. P., Brum, W. S., Hauschild, L. A., Ros, L. U. D., Ferreira, P. C. L., Bellaver, B., Leffa, D. T., Bieger, A., Tissot, C., Lussier, F. Z., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.12.008 · Cited by 43
Jiang, X., Zhou, J., Wang, Y., Chen, L., Duan, Y., Huang, J., Liu, C., Chen, Y., Liu, W., Sun, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112751 · Cited by 39
Hu, Y., Cho, M., Sachdev, P., Dage, J., Hendrix, S., Hansson, O., Bateman, R. J., & Hampel, H. (2024) · Med · doi:10.1016/j.medj.2024.08.004 · Cited by 42
Isorhynchophylline alleviates learning and memory impairments induced by aluminum chloride in mice
Li, H., Ip, S., Zheng, G., Xian, Y., & Lin, Z. (2018) · Chinese Medicine · doi:10.1186/s13020-018-0187-8 · Cited by 43
Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease
Pons, V., & Rivest, S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000400 · Cited by 43
“Here again, however, most of clinical trials failed in phase III, whereas some treatments even worsen cognitive decline and induced side effects (Doody et al., 2013; Honig et al., 2018; P. Liu et al., 2019).”
BackgroundJeong, S. Y., Suh, C. H., Shim, W. H., Lim, J., Lee, J., & Kim, S. J. (2022) · Neurology · doi:10.1212/wnl.0000000000201019 · Cited by 60
“001; Figures 2 and 3) compared with other agents.(15-34)”
BackgroundMethodResultInfluentialQiao, Y., Gu, J., Yu, M., Chi, Y., & Ma, Y. (2024) · CNS Drugs · doi:10.1007/s40263-024-01067-2 · Cited by 38
Proteases: Pivot Points in Functional Proteomics
Verhamme, I. M., Leonard, S. E., & Perkins, R. C. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8814-3_20 · Cited by 46
Endosomal dysfunction impacts extracellular vesicle release: Central role in Aβ pathology
Arbo, B. D., Cechinel, L. R., Palazzo, R. P., & Siqueira, I. R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.101006 · Cited by 38
Bullain, S., & Doody, R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 38
“…antibodies, including bapineu-zumab (Rinne et al., 2010; Salloway et al., 2009, 2014), solanezumab (Doody et al., 2014; Farlow et al., 2012; Honig et al., 2018; Siemers et al., 2010), aducanumab (Biogen, 2019; ClinicalTrials.gov, 2019q [NCT02477800]; Sevigny et al., 2016;…”
Peli1 impairs microglial Aβ phagocytosis through promoting C/EBPβ degradation
Xu, J., Yu, T., Pietronigro, E. C., Yuan, J., Arioli, J., Pei, Y., Luo, X., Ye, J., Constantin, G., Mao, C., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000837 · Cited by 38
Schwarz, A. J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01027-4 · Cited by 42
“By way of example, CSF Aβ1-42 has been used as an alternative to amyloid PET in the screening phase for AD trials to accommodate geographies with differing availability of the two methods [9], and CSF markers of Aβ and tau (phosphorylated tau and total tau) have been frequently used as alternative outcome biomarkers r…”
MethodNair, A., Rutledge, R. B., & Mason, L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00140 · Cited by 37
“This is analogous to the use of biomarkers in clinical trials being used as secondary outcomes— for example, changes in amyloid-beta measures in clinical trials for Alzheimer dementia may suggest possible treatment efficacy even if no change is seen in cognitive scores (18).”
MethodProspective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
Akter, R., Rahman, H., Behl, T., Chowdhury, M. A. R., Manirujjaman, M., Bulbul, I. J., Elshenawy, S. E., Ţiţ, D. M., & BUNGAU, S. G. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210218084444 · Cited by 44
Passive immunotherapy for Alzheimer’s disease: challenges & future directions
Yi, L., Tan, E. K., & Zhou, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05248-x · Cited by 49
“The formation of ADA has also been identified in AD patient serum in passive immunotherapy trials with crenezumab (an anti-Aβ antibody), tilavonemab (an anti-tau antibody) and solanezumab [13, 17, 35].”
BackgroundPadilla-Godínez, F. J., Vázquez-García, E. R., Trujillo-Villagrán, M. I., Soto-Rojas, L. O., Palomero‐Rivero, M., Hernández-González, O., Pérez-Eugenio, F., Collazo-Navarrete, O., Arias-Carrión, Ó., & Guerra‐Crespo, M. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1570553 · Cited by 47
“In AD, immunotherapy has shown more promise despite initial setbacks with drugs like bapineuzumab, solanezumab, and crenezumab (Salloway et al., 2014; Cummings et al., 2018; Honig et al., 2018).”
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
Willis, B. A., Sundell, K., Lachno, D. R., Ferguson‐Sells, L. R., Case, M. G., Holdridge, K., DeMattos, R. B., Raskin, J., Siemers, E. R., & Dean, R. A. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.001 · Cited by 37
“EXPEDITION3 was a multicenter, international, randomized study designed to confirm the secondary efficacy analyses from EXPEDITION and EXPEDITION2 [5].”
BackgroundResultInfluentialSelf-citationCSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
Boumenir, A., Cognat, E., Sabia, S., Hourrègue, C., Lilamand, M., Dugravot, A., Bouaziz-Amar, É., Laplanche, J., Hugon, J., Singh‐Manoux, A., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0481-4 · Cited by 40
Biomarkers: Our Path Towards a Cure for Alzheimer Disease
Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 46
Nie, Y., Yang, J., Zhou, L., Yang, Z., Liang, J., Liu, Y., Ma, X., Qian, Z., Hong, P., Kalueff, A. V., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02403-3 · Cited by 41
Review of Alzheimer’s disease drugs and their relationship with neuron-glia interaction
Ajenikoko, M. K., Ajagbe͓, A. O., Onigbinde, O. A., Okesina, A. A., & Tijani, A. A. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.11.005 · Cited by 44
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 46
Enhancing Agriculture Through AI Vision and Machine Learning: The Evolution of Smart Farming
Padhiary, M., & Kumar, R. (2024) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3693-5380-6.ch012 · Cited by 64
Lippi, S. L. P., Smith, M. L., & Flinn, J. M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00382 · Cited by 36
“In addition, drug research focusing on Aβ has consistently failed to produce significant clinical findings (Doig et al., 2017; Honig et al., 2018), leading to no new drugs on the market since the early 2000s.”
BackgroundN‐terminal heterogeneity of parenchymal and vascular amyloid‐β deposits in Alzheimer’s disease
Zampar, S., Klafki, H., Sritharen, K., Bayer, T. A., Wiltfang, J., Rostagno, A. A., Ghiso, J. A., Miles, L. A., & Wirths, O. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12637 · Cited by 37
Xu, Y., Zhao, M.-N., Zhou, D., Zheng, T., & Zhang, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111360 · Cited by 38
Defective Autophagy and Mitophagy in Alzheimer’s Disease: Mechanisms and Translational Implications
Chen, J., He, H., Ye, Q., Feng, F., Wang, W., Gu, Y., Han, R., & Xie, C. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02487-7 · Cited by 37
Boada, M., López, O. L., Olazarán, J., Núñez, L., Pfeffer, M., Puente, O. A., Piñol‐Ripoll, G., Gámez, J. E., Anaya, F., KIPROV, D. D., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12477 · Cited by 40
Self-citationSystematic Multi-Domain Alzheimer’s Risk Reduction Trial (SMARRT): Study Protocol
Yaffe, K. S., Barnes, D. E., Rosenberg, D. E., Dublin, S., Kaup, A. R., Ludman, E. J., Vittinghoff, E., Peltz, C. B., Renz, A. D., Adams, K. J., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180634 · Cited by 44
Bad news and good news in AD, and how to reconcile them
Knopman, D. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0131-7 · Cited by 35
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., & Raheem, A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00845-5 · Cited by 49
“Previous monoclonal antibodies (mABs), such as solan-ezumab, crenazumab, and bapinuezemab, did not achieve the primary efficacy goals in studies focused on symptomatic AD [33, 34].”
BackgroundNonino, F., Minozzi, S., Sambati, L., Del Giovane, C., Baldin, E., Bassi, M. C., De Santis, C., Gonzalez-Lorenzo, M., Vignatelli, L., Filippini, G., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016297 · Cited by 35
Roe, S. M., Wahab, B., Török, Z., Horváth, I., Vígh, L., & Prodromou, C. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00051 · Cited by 36
“This is all the timelier since the announcement of a variety of clinical trial failures including those for idalopirdine and intepirdine, selective 5-hydroxytryptamine-6 receptor antagonists, and solanezumab, an Aβ antibody (Atri et al., 2018; Honig et al., 2018; Simpson, 2018).”
BackgroundRe-thinking Alzheimer's disease therapeutic targets using gene-based tests
Kwok, M. K., Lin, S. L., & Schooling, C. M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.001 · Cited by 35
“However, failure of anti-Aβ drugs has raised questions about the causal role of amyloid protein in AD and the relevance of the amyloid protein hypothesis to AD drug development [15,16].”
BackgroundTrazodone use and risk of dementia: A population-based cohort study
Brauer, R., Lau, W. C. Y., Hayes, J. F., Man, K. K. C., Osborn, D. P. J., Howard, R., Kim, J., & Wong, I. C. K. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002728 · Cited by 35
The Brain–Heart Axis: Alzheimer’s, Diabetes, and Hypertension
Riching, A. S., Major, J. L., Londono, P., & Bagchi, R. A. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00091 · Cited by 37
Blood-based biomarkers in Alzheimer’s disease: a mini-review
Padala, S. P., & NEWHOUSE, P. A. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01114-1 · Cited by 41
“Similarly, participants in the A4 study with elevated amyloid concentrations receive solanezumab, another monoclonal antibody which targets Aβ, in an effort to observe its effect on memory loss (Honig et al. 2018).”
BackgroundLessons from antiamyloid-β immunotherapies in Alzheimer's disease
Plascencia‐Villa, G., & Perry, G. L. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00019-9 · Cited by 40
Rationale for the development of an Alzheimer’s disease vaccine
Kwan, P., Konno, H., Chan, K. Y., & Baum, L. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1665453 · Cited by 33
“However, a subsequent trial in prodromal AD showed no effect on cognitive decline.(61) Ponezumab binds the C-terminal of Aβ but did not affect CSF Aβ or decline of cognition in AD.”
BackgroundCurrent and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 38
Tan, L. Y., Yeo, X. Y., Bae, H., Lee, D. P. S., Ho, R., Kim, J. E., Jo, D., & Jung, S. (2021) · Life · doi:10.3390/life11070698 · Cited by 36
“Furthermore, the most promising Aβ-targeting monoclonal antibodies, with a similar mechanism of action and aims to aducanumab, such as solanezumab, bapineuzumab, crenezumab, and gantenerumab, have failed their respective Phase III trials [81,82].”
BackgroundYou, T.-Y., Dong, Q., & Cui, M. (2022) · Aging and Disease · doi:10.14336/ad.2022.1204 · Cited by 43
“However, several lines of evidence indicate that the levels of amyloid-β peptides (Aβ) do not affect the severity of cognitive dysfunction [102, 103].”
BackgroundBaviskar, P. S., & Mahajan, H. S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102990 · Cited by 47
Clinical trials of prion disease therapeutics
Forloni, G., Roiter, I., & Tagliavini, F. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.019 · Cited by 37
Genetic Variants and Oxidative Stress in Alzheimer’s Disease
Kowalska, M., Wize, K., Prendecki, M., Lianeri, M., Kozubski, W. P., & Dorszewska, J. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200224121447 · Cited by 36
Koike, H., Iguchi, Y., Sahashi, K., & Katsuno, M. (2021) · Molecules · doi:10.3390/molecules26165091 · Cited by 36
“For Alzheimer’s disease, other monoclonal antibodies, including gantenerumab [70], solanezumab [71], and lecanemab [72], could also be up for approval.”
BackgroundMullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Joie, R. L., Cummings, J. L., Dage, J. L., Galasko, D. R., Ikonomović, M. D., Karikari, T. K., Landau, S. M., Llibre‐Guerra, J. J., Mummery, C. J., Ossenkoppele, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70997 · Cited by 38
“This contrasts with datafromsolanezumabandbapineuzumabtreatments,whichareasso-ciated with no-to-mild decrease in amyloid-PET levels 33,34 and were not associated with clear changes in the density of A β deposits at autopsy,showingonlysubtlebiochemicalalterations.”
Chen, L., Cruz, E., Oikari, L. E., Padmanabhan, P., Song, J. H., & Götz, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114517 · Cited by 38
Decourt, B., Noorda, K., Noorda, K. J., Shi, J., & Sabbagh, M. N. (2022) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265626 · Cited by 34
“However, Expedition 3 was discontinued in 2016 due to a lack of evidence to support a reduction in cognitive decline in AD participants at week 80.(132) Similarly, ExpeditionPRO (NCT02760602), which enrolled prodromal AD subjects, was terminated in 2017 because of a lack of evidence that solanezumab would slow cogniti…”
BackgroundKeramidis, I., McAllister, B. B., Bourbonnais, J., Wang, F., Isabel, D., Rezaei, E., Sansonetti, R., Degagne, P., Hamel, J. P., Nazari, M., et al. (2023) · Brain · doi:10.1093/brain/awad250 · Cited by 40
Cheng, B., Li, Y., Ma, L., Wang, Z., Petersen, R. B., Zheng, L., Chen, Y., & Huang, K. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.02.013 · Cited by 33
“However, solanezumab and bapineuzumab failed to meet clinical endpoints in the phase III clinical trials [218, 219], and solanezumab did not significantly reduce cognitive decline in AD patients [220].”
BackgroundPredicting clinical progression trajectories of early Alzheimer's disease patients
Devanarayan, V., Ye, Y., Charil, A., Andreozzi, E. M., Sachdev, P., Llano, D. A., Tian, L., Zhu, L., Hampel, H. J., Kramer, L. D., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13565 · Cited by 35
The Impact of Anti-Amyloid Immunotherapies on Stroke Care
Bilodeau, P., Dickson, J. R., & Kozberg, M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051245 · Cited by 33
Dementia treatment versus prevention
Perneczky, R. (2019) · Phlebolymphology · doi:10.31887/dcns.2019.21.1/rperneczky · Cited by 45
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Imbimbo, B. P., Lozupone, M., Watling, M., & Panza, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1795127 · Cited by 31
Wei, H., Masurkar, A. V., & Razavian, N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1149036 · Cited by 35
“This has important implications for clinical trials for agents that target βamyloid clearance (Wirz-Justice, 1986; Kurz and Perneczky, 2011; Ostrowitzki et al., 2017; Honig et al., 2018; Egan et al., 2019; Huang et al., 2020; NIA, 2021; van Dyck et al., 2023) or other subtypespecific neuropathologies.”
BackgroundJin, M., & Noble, J. M. (2024) · eNeuro · doi:10.1523/eneuro.0088-24.2024 · Cited by 39
“…in a new RCT. Collectively, results of the aducanumab trials re fl ected outcomes of several other anti-A β MAB trials demonstrating variable levels of convincing amyloid target engagement but disappointing clinical impacts (Salloway et al., 2014, 2021; Honig et al., 2018; Bateman et al., 2023).”
ResultDonepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease
Mezeiová, E., Chalupova, K., Nepovimová, E., Górecki, L., Prchal, L., Maliňák, D., Kuča, K., Soukup, O., & Korábečný, J. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190228122956 · Cited by 36
A metabolic perspective of late onset Alzheimer’s disease
Ettcheto, M., Cano, A. C., Busquets, O., Manzine, P. R., Sánchez‐López, E., Castro-Torres, R. D., Beas‐Zárate, C., Verdaguer, E., García, M. L., Olloquequi, J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104255 · Cited by 34
Molecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 34
Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies
Yang, H., Li, J., Li, X., Ma, L., Hou, M., Zhou, H., & Zhou, R. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.927530 · Cited by 34
Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model
Oliveira, D. V., Coupland, K., Shao, W., Jin, S., Gaudio, F. D., Wang, S., Fox, R., Rutten, J. W., Sandin, J., Zetterberg, H., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216556 · Cited by 36
A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Ralvenius, W. T., Mungenast, A. E., Woolf, H., Huston, M. M., Gillingham, T. Z., Godin, S. K., Penney, J., Cam, H. P., Gao, F., Fernandez, C. G., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20222105 · Cited by 29
“However, multiple previous drug candidates that successfully cleared β -amyloid were abandoned prematurely due to adverse effects, lack of efficacy in cognitive tests, or both (Doody et al., 2013; Egan et al., 2018; Honig et al., 2018).”
Lecanemab: More Questions Than Answers!
Kaur, U., Reddy, J., Tiwari, A., Chakrabarti, S., & Chakrabarti, S. S. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01331-1 · Cited by 30
“For example, ARIA was uncommon in trials of solanezumab, another monoclonal antibody targeting only the soluble monomeric form of Aβ, which failed to demonstrate clinical efficacy [26].”
Neurodegenerative diseases have genetic hallmarks of autoinflammatory disease
Richards, R. I., Robertson, S. A., & Kastner, D. L. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy139 · Cited by 29
“The disappointing results (1,2) of recent clinical trials of interventions targeting amyloid-b aggregation have shifted the focus to alternative hypotheses.”
BackgroundChen, J., Duan, Y., Li, H., Lu, L., Liu, J., & Tang, C. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s210062 · Cited by 38
“However, recently, several drug experiments have been terminated in phase 3 or 4, because they did not meet any of their co-primary efficacy endpoints.(2,3) Thus, pharmacotherapy research on AD is at a bottleneck.”
BackgroundDifferential activation of the mTOR/autophagy pathway predicts cognitive performance in APP/PS1 mice
Vartak, R. S., Rodin, A., & Oddo, S. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.018 · Cited by 29
Tian, J., Shi, J., Wei, M., Ni, J., Fang, Z., Gao, J., Wang, H., Yao, H., Zhang, J., Li, J., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.03.001 · Cited by 31
“different Ab antibodies (solanezumab and verubecestat) did not reduce cognitive or functional decline in patients with mild-to-moderate AD [23,24].”
BackgroundChen, G., Yang, K. Y., Du, W., Hu, X., & Han, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190501 · Cited by 30
Hettmann, T., Gillies, S. D., Kleinschmidt, M., Piechotta, A., Makioka, K., Lemere, C. A., Schilling, S., Rahfeld, J., & Lues, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-60319-5 · Cited by 29
Fujino, T., Hossain, M. S., & Mawatari, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-60204-8_14 · Cited by 36
Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission
Kreis, A., Desloovere, J., Suelves, N., Pierrot, N., Yerna, X., Issa, F., Schakman, O., Gualdani, R., de Clippele, M., Tajeddine, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97144-3 · Cited by 32
Dantas, J. M., Mutarelli², A. M., Navalha, D. D. P., Dagostin, C. S., Romeiro, P. H. C. L., Felix, N. S., Nogueira, A., Batista, S., Teixeira, L., & Caramelli, P. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07194-w · Cited by 32
Dubbelman, M. A., Hendriksen, H. M. A., Harrison, J., Vijverberg, E. G. B., Prins, N. D., Kroeze, L. A., Ottenhoff, L., van Leeuwenstijn, M. S. S. A., Verberk, I. M. W., Teunissen, C. E., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207978 · Cited by 27
Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2024) · Brain · doi:10.1093/brain/awae216 · Cited by 39
Zhuang, X., Jie, L., Song, Y., Ban, R., Zhao, X., Xia, Z., Wang, Z., & Zhang, G. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08815-z · Cited by 35
“Aducanumab (Aduhelm) (Arndt et al., 2018), lecanemab (Lecanemab-irmb, BAN2401, Leqembi) (Swanson et al., 2021), donanemab (donanemab-azbt, LY3002813, Kisunla) (Min-tun et al., 2021), and solanezumab (LY2062430) (Honig et al., 2018) are among the antibodies that have shown some effects in clinical trials.”
Tonegawa‐Kuji, R., Hou, Y., Hu, B., Lorincz‐Comi, N. J., Pieper, A. A., Tousi, B., Leverenz, J. B., & Cheng, F. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004568 · Cited by 36
“For example, for AD stage, among the trials classified as “early”, EXPEDITION 3 (which tested solanezumab), only included patients with mild AD but not MCI [16].”
InfluentialWatari, H., Shimada, Y., Matsui, M., & Tohda, C. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/4086749 · Cited by 29
Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition
Ozlen, H., Binette, A. P., Köbe, T., Meyer, P., Gonneaud, J., St‐Onge, F., Provost, K., Soucy, J., Rosa‐Neto, P., Breitner, J. C. S., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2442 · Cited by 34
Caramelli, B., Yu, P. C., Cardozo, F. A. M., Magalhães, I. R., Spera, R. R., Amado, D. K., Escalante-Rojas, M. C., Gualandro, D. M., Calderaro, D., Tavares, C. A. M., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02563-2 · Cited by 34
Loftus, J. R., Puri, S., & Meyers, S. P. (2023) · Insights into Imaging · doi:10.1186/s13244-022-01358-6 · Cited by 33
Salemme, S., Ancidoni, A., Locuratolo, N., Piscopo, P., Lacorte, E., Canevelli, M., & Vanacore, N. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2284305 · Cited by 28
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30
Sato, S., Hatakeyama, N., Fujikoshi, S., Katayama, S., Katagiri, H., & Sims, J. R. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00604-x · Cited by 30
Human neural stem cell-derived artificial organelles to improve oxidative phosphorylation
Wang, J., Zhao, M., Wang, M., Fu, D., Lin, K., Xu, Y., Shen, L., Jin, S., Wang, L., & Liu, J. (2024) · Nature Communications · doi:10.1038/s41467-024-52171-2 · Cited by 34
“Consistent with the behavioral results, SAO treatment also signi fi cantly reduced brain tissue loss at 29 days after treatment of the MCAO model (Fig.”
InfluentialAlzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I. A., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 35
Lutz, B. M., & Peng, J. (2018) · Proteomes · doi:10.3390/proteomes6040046 · Cited by 27
“Unfortunately, clinical trials implementing Aβ antibody therapy or pharmacological intervention of APP cleavage have not yet been successful [21,22].”
BackgroundEstablishment of a Risk Prediction Model for Mild Cognitive Impairment Among Elderly Chinese
Wang, B., Shen, T., Mao, L., Xie, L., Fang, Q., & Wang, X. (2020) · The journal of nutrition health & aging · doi:10.1007/s12603-020-1335-2 · Cited by 29
Acetylation of Aβ42 at Lysine 16 Disrupts Amyloid Formation
Adhikari, R., Yang, M., Saikia, N., Dutta, C., Alharbi, W. F. A., Shan, Z. J., Pandey, R., & Tiwari, A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00069 · Cited by 29
Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity
Limegrover, C. S., LeVine, H., Izzo, N. J., Yurko, R., Mozzoni, K., Rehak, C., Sadlek, K., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15212 · Cited by 24
“Monoclonal antibodies with high affinity for monomer, such as solanezumab, have not been clinically efficacious (Doody et al., 2014; Honig et al., 2018).”
BackgroundReiss, A. B., Montufar, N., DeLeon, J. R., Pinkhasov, A., Gomolin, I. H., Glass, A. D., Arain, H. A., & Stecker, M. M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000320 · Cited by 28
Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer’s Disease
Fülöp, T., Tripathi, S., Rodrigues, S., Desroches, M., Bunt, T., Eiser, A. R., Bernier, F., Beauregard, P. B., Barron, A. E., Khalil, A., et al. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s264910 · Cited by 27
Disease‐specific interactome alterations via epichaperomics: the case for Alzheimer’s disease
Ginsberg, S. D., Neubert, T. A., Sharma, S., Digwal, C. S., Yan, P., Timbus, C., Wang, T., & Chiosis, G. (2021) · FEBS Journal · doi:10.1111/febs.16031 · Cited by 30
Yu, J., He, Y., Yu, X., Gu, L., Wang, Q., Wang, S., Tao, F., & Sheng, J. (2022) · Biological Trace Element Research · doi:10.1007/s12011-022-03136-3 · Cited by 28
The Current Landscape of Prevention Trials in Dementia
Lee, J., Howard, R. S., & Schneider, L. S. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01236-5 · Cited by 31
“While displaying a favorable safety profile in three phase 3 trials, including the third trial limited to participants with mild AD (EXPEDITION 3), solanezumab failed to show clinical benefits on its primary outcomes after 80 weeks of treatment [48].”
BackgroundMahaman, Y. A. R., Feng, J., Huang, F., Salissou, M. T. M., Wang, J., Liu, R., Zhang, B., Li, H., Zhu, F., & Wang, X. (2022) · Nutrients · doi:10.3390/nu14204284 · Cited by 35
Kang, S., Ha, S., Park, H., Nam, E., Suh, W. H., Suh, Y., & Chang, K. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00273 · Cited by 28
“During the last decade, all phase III clinical trials including promising candidates, such as Solanezumab and Verubecestat have failed because of adverse effects and the lack of cognitive improvement (Egan et al., 2018; Honig et al., 2018).”
Background
Metadata
- Authors
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From the Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III–Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC — both in Australia (M.W.); Fundació ACE, Alzheimer Research...
- Western University (CA)
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-25
- Volume
- 378
- Issue
- 4
- Pages
- 321-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787612390
- Cited by
- 1,049
- References
- 27
- Citations by year
- 2026: 48 · 2025: 93 · 2024: 121 · 2023: 123 · 2022: 136 · 2021: 129 · 2020: 169 · 2019: 136 · 2018: 91
- FWCI
- 90.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Publisher
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, mild dementia, amyloid-beta, humanized monoclonal antibody, amyloid-beta clearance, cognitive decline, florbetapir PET, cerebral edema, treatment efficacy, amyloid plaques, neurofibrillary tangles
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, Immunotherapy, Infusions, Intravenous, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Treatment Failure, Positron-Emission Tomography, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.